Medicure is a specialty pharmaceutical company established in 1997. The Company’s vision is to become a leading specialty pharmaceutical company in the commercialization and development of unique small molecule pharmaceuticals in the cardiovascular and neurological fields for unmet medical needs. LEAD PRODUCTS 1) AGGRASTAT® - US GP IIb/IIIa inhibitor market - $450 million (AGGRASTAT® + two competitors) 2) TARDOXALTM – in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need

Medicure is focused on growing revenues through its US sales and marketing subsidiary, Medicure Pharma Inc., and building value from other R&D initiatives. Medicure’s commercial business is focused on Aggrastat®, one of three products competing within the >US$450 million market for GP IIb/IIIa inhibitors, a cardiovascular product for treatment of Acute Coronary Syndromes. The primary focus of Medicure’s R&D activities is the clinical development of TARDOXALTM in the treatment of dyskinesias and other movement related disorders. GROWTH AND REVENUE To build and maximize shareholder value through: 1) Increasing Commercial Revenue from Aggrastat® sales 2) Development of TARDOXALTM through Phase II for partnering CONTACT Albert Friesen, PhD President & CEO adfriesen@medicure.com 204.487.7412 ext. 231